Xencor (XNCR) Competitors

Xencor (NASDAQ:XNCR) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking and media sentiment.

Is XNCR or ACAD more profitable?

ACADIA Pharmaceuticals has a net margin of 13.83% compared to Xencor's net margin of -232.77%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-232.77%	-30.92%	-21.74%
ACADIA Pharmaceuticals	13.83%	25.83%	14.71%

Do analysts rate XNCR or ACAD?

Xencor currently has a consensus price target of $33.86, indicating a potential upside of 249.04%. ACADIA Pharmaceuticals has a consensus price target of $23.93, indicating a potential upside of 62.48%. Given Xencor's stronger consensus rating and higher probable upside, equities analysts plainly believe Xencor is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
ACADIA Pharmaceuticals	0 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the media prefer XNCR or ACAD?

In the previous week, ACADIA Pharmaceuticals had 16 more articles in the media than Xencor. MarketBeat recorded 20 mentions for ACADIA Pharmaceuticals and 4 mentions for Xencor. ACADIA Pharmaceuticals' average media sentiment score of 1.00 beat Xencor's score of 0.77 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals have more ownership in XNCR or ACAD?

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 5.2% of Xencor shares are held by company insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Which has more volatility and risk, XNCR or ACAD?

Xencor has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.

Which has stronger valuation & earnings, XNCR or ACAD?

ACADIA Pharmaceuticals has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$110.49M	6.19	-$126.09M	-$3.51	-2.76
ACADIA Pharmaceuticals	$957.80M	2.57	-$61.29M	$1.36	10.83

Does the MarketBeat Community believe in XNCR or ACAD?

ACADIA Pharmaceuticals received 391 more outperform votes than Xencor when rated by MarketBeat users. However, 73.16% of users gave Xencor an outperform vote while only 73.07% of users gave ACADIA Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Xencor	Outperform Votes 507 73.16%	Underperform Votes 186 26.84%
ACADIA Pharmaceuticals	Outperform Votes 898 73.07%	Underperform Votes 331 26.93%

Summary

ACADIA Pharmaceuticals beats Xencor on 13 of the 19 factors compared between the two stocks.